Roivant Sciences Ltd. (NASDAQ: ROIV) is considered one of the best stocks to buy under $20.
On September 17, Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study. This 52-week, placebo-controlled trial evaluated the once-daily oral drug brepocitinib in patients with dermatomyositis (DM).
The trial enrolled 241 subjects globally and is noted as a significant development in the treatment of this rare muscle disease. These promising results highlight Roivant’s potential in advancing innovative therapies and support its position as a compelling investment opportunity.
https://ca.finance.yahoo.com/news/roivant-brepocitinib-phase-3-dermatomyositis-205446652.html
